Plasma concentrations and role of macrophage inflammatory protein-1α during chronic Schistosoma mansoni infection in humans

Journal of Infectious Diseases

Volumn 186, Issue 11, 2002, Pages 1696-1700

  Falcão, Patrícia L ^a   Correa Oliveira, Rodrigo ^b   Fraga, Lúcia A O ^c   Talvani, André ^a   Proudfoot, Amanda E I ^d   Wells, Tim N C ^d   Williams, Timothy J ^e   Jose, Peter J ^e   Teixeira, Mauro M ^a,b  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^b Laboratory of Medical Entomology   (Brazil)

^c UNIVERSIDADE VALE DO RIO DOCE   (Brazil)

^d SERONO PHARMACEUTICAL RES INSTITUTE   (Switzerland)

^e IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE; CHEMOKINE RECEPTOR; EOTAXIN; INTERLEUKIN 8; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MONOCYTE CHEMOTACTIC PROTEIN 1; RANTES; RECEPTOR BLOCKING AGENT;

ADULT; ARTICLE; BLOOD LEVEL; CONTROLLED STUDY; DISEASE SEVERITY; ENTEROPATHY; FEMALE; GRANULOMATOUS INFLAMMATION; HEPATOSPLENOMEGALY; HUMAN; INFECTION RISK; MAJOR CLINICAL STUDY; MALE; NONHUMAN; ONCOGENE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; SCHISTOSOMA MANSONI; SCHISTOSOMIASIS;

ADULT; ANIMALS; CHEMOKINES, CC; CHRONIC DISEASE; FEMALE; HUMANS; MACROPHAGE INFLAMMATORY PROTEIN-1; MALE; PARASITE EGG COUNT; RANTES; SCHISTOSOMA MANSONI; SCHISTOSOMIASIS MANSONI;

EID: 0036891394     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/345370     Document Type: Article

References (13)

1. Mackay CR. Chemokines: Immunology's high impact factors. Nat Immunol 2001;2:95-101.
2. Gerard C, Rollins BJ. Chemokines and disease. Nat Immunol 2001;2:108-15.
3. Proudfoot AE, Power CA, Wells TN. The strategy of blocking the chemokine system to combat disease. Immunol Rev 2000;177:246-56.
4. Neves J, Raso P. Anatomo-clinical study of a case of schistosomiasis mansoni, toxemic form, evolving into a hepatosplenic form within 130 days (hepatic fibrosis, Symmers type). Rev Inst Med Trop Sao Paulo 1965;7:256-66.
5. Fallon PG. Immunopathology of schistosomiasis: A cautionary tale of mice and men. Immunol Today 2000;21:29-35.
6. Ross AG, Bartley PB, Sleigh AC, et al. Schistosomiasis. N Engl J Med 2002;346:1212-20.
7. Falcão PL, Malaquias LC, Martins-Filho OA, et al. Human Schistosomiasis mansoni: IL-10 modulates the in vitro granuloma formation. Parasite Immunol 1998:20:447-54.
8. Doughty BL, Ottesen EA, Nash TE, Phillips SM. Delayed hypersensitivity granuloma formation around Schistosoma mansoni eggs in vitro. III. Granuloma formation and modulation in human Schistosomiasis mansoni. J Immunol 1984:133:993-7.
9. Chensue SW. Molecular machinations: Chemokine signals in host-pathogen interactions. Clin Microbiol Rev 2001:14:821-35.
10. Proudfoot AE, Power CA, Hoogewerf AJ, et al. Extension of recombinant human RANTES by the retention of the initiating methionine produces a potent antagonist. J Biol Chem 1996:271:2599-603.
11. Mwatha JK, Kimani G, Kamau T, et al. High levels of TNF, soluble TNF receptors, soluble ICAM-I. and IFN-γ, but low levels of IL-5, are associated with hepatosplenic disease in human schistosomiasis mansoni. J Immunol 1998:160:1992-9.
12. Lukacs NW, Kunkel SL, Strieter RM, Warmington K, Chensue SW. The role of macrophage inflammatory protein 1 alpha in Schistosoma mansoniegg-induced granulomatous inflammation. J Exp Med 1993;177:1551-9.
13. Oliveira DM, Silva-Teixeira DN, Gustavson S, Oliveira SM, Goes AM. Nitric oxide interaction with IL-10, MIP-1alpha, MCP-1 and RANTES over the in vitro granuloma formation against different Schistosoma mansoni antigenic-preparations on human schistosomiasis. Parasitology 2000;120:391-8.